Toinv, I couldn't agree with you more regarding the corporate management at RVX. In no way do I think Don is stupid and he deserves all the credit in the world for a long time ago being instrumental in getting Resverlogix up and running.  It would seem though that he has fallen into a common entrepreneurial trap and that is not understanding what your strengths are and thus when to pass the torch to someone whose strengths better match the current situation and go forward.  

Don for some time has seemed out of his depth when it comes to structuring finance for a public corporation, when it comes to modelling a business plan for a development company with very long major event horizons (cardiovascular drug development is that in spades), when it comes to managing PR for a public corporation and when it comes to making presentations involving the science of the company. The last point would seem to be an opinion that is shared by the market as for quite some time his presentations have not resulted in market sentiment stating "we want a piece of this".  RVX has clearly become a "show me" story where the market does not believe in any company projections and will only respond to very solid, regular news as for RVX news will likely have a short shelf life wrt sp due to a completely abysmal track record for follow through on just about anything. This makes financing more expensive than for a well run company. I actually believe if this was another company with a reputable CEO/track record that news of the Covid potential alone of Apabetalone would have already given a meaningful lift to the sp. 

I hope at the very least going forward that for press releases regarding the science the company will start using quotes from company scientists or even better from members of the scientific advisory committees, many of whom have stellar international reputations.  Share price action would indicate nobody cares about what Don's opinion is, and it would seem much smarter to have opinions from experts in respective fields on the potential of Apabetalone as treatment in a particular field. I also hope the company will also consider involving company scientists in presentations involving the science. The optics will be infinitely improved and science questions such as BKC's on LDL screening will not be bungled while an audience is listening. To me complete professionalism in any future public presentations is absolutely essential if RVX wants to restore some credibility with retail investors who as we all know are currently the ones setting the market price.